Biohaven's Taldefgrobep Alfa Shifts Focus from SMA Failure to Promising Obesity Trial

Biohaven's investigational drug, taldefgrobep alfa, did not achieve its intended objective in the Phase III trial meant to improve motor function in spinal muscular atrophy (SMA) patients. The trial showed that taldefgrobep alfa failed to outperform the placebo on the Motor Function Measurement-32 (MFM-32) scale, with no significant motor function advancement observed[1][2][3]. Despite the setback, Biohaven is engaging in talks with the FDA to explore potential opportunities for specific patient groups who demonstrated efficacy signals, particularly among Caucasian participants[1][2]. The study did highlight a notable reduction in body fat, leading Biohaven to shift its focus towards initiating a Phase II trial aimed at obesity by the end of the year[1][3].